BioSig to Participate in the The Benchmark Company 10th Annual Discovery Conference
November 17 2021 - 9:45AM
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it would participate in The Benchmark
Company 10th Annual Discovery One on One Investor Conference
(Virtual) on Thursday, December 2, 2021.
The Company’s executive leadership will provide a business
update on the roll-out of its FDA 510(k) cleared medical device,
the PURE EP™ System, that aims to drive procedural efficiency and
efficacy in cardiac electrophysiology and outline key priorities
for the next phase of its commercial and clinical growth. To date,
73 physicians have completed over 1700 patient cases with the PURE
EP™ System. The Company is in a focused commercial launch of the
PURE EP™ System in the Northeast, Texas, and Florida. The
technology is regularly used in some of the country’s
highest-ranked hospitals, including St. David’s Medical Center in
Austin, TX, Mayo Clinic campuses in Florida, Minnesota, and
Arizona, and University of Pennsylvania in Philadelphia, PA. The
Company recently completed its first clinical trial and is hosting
a roundtable to discuss the results. The event, led by the three
industry experts, will be held on November 18, 2021, at 8 pm
ET.
The Benchmark Company 10th Annual Discovery One on One Investor
ConferenceDate: Thursday, December 2nd,
2021Time: 8 am – 4 pm ESTFor parties
interested in scheduling a one-on-one meeting with BioSig
management, please contact the conference
coordinators at:
events@benchmarkcompany.com
About The Benchmark Company Discovery
ConferenceThe Annual Benchmark Company Discovery
Conference is hosted by The Benchmark Company, a boutique
investment banking firm headquartered in New York, with regional
offices across the country. Benchmark provides Research, Sales,
Trading, and Investment Banking services to public and private
companies, institutional and high net worth investors, and family
offices. The conference is regularly attended by more than 150
institutional investors and will feature approximately 50
presenting companies.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP™ System is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording, and storing
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024